Nymox Pharmaceutical Corp. (NYMX) reported a third-quarter net loss of $1.36 million or $0.04 per share, compared to a loss of $1.32 million or $0.04 per share in the year ago quarter.
For the nine months ending September 30, 2009, Nymox reported a net loss of $3.59 million or $0.12 per share, compared to a loss of $3.71 million or $0.13 per share for the nine months ending September 30, 2008.
Net losses include stock compensation charges for the quarter of $322,808 in 2009 and $293,180 in 2008 and for the nine months of $881,344 in 2009 and $702,540 in 2008. The increase of the net loss for the quarter is mainly attributable to expenses relating to the launch of Phase 3 clinical trials for NX-1207.
The decrease in net losses for the nine months period is attributable to reduced general and administrative expenditures compared to 2008. Product sales amounted to $71,904 for the quarter and $248,471 for the nine months ending September 30, 2009, compared to $82,171 and $306,849 for the same periods in 2008 due to a decrease in sales attributable to the current economic slowdown.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.